Could a single drug shield kidneys during heart surgery?

NCT ID NCT07625553

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug R2R01 can prevent acute kidney injury in people at high risk who are having heart surgery with a heart-lung machine. Participants receive either R2R01 or a placebo before and after surgery. The goal is to see if the drug reduces kidney damage and related complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

R2R01 (a relaxin agonist)

What this could lead to

If successful, this could lead to a new way to prevent kidney damage after heart surgery, reducing complications and hospital stays.

What could go wrong

This is an early phase 2 trial, so the drug may not prove effective or safe. Possible side effects are still being studied.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • IRCSS San Raffaele

    RECRUITING

    Milan, 20132, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••